NCT01918826

Brief Summary

The Charcot syndrome Marie Tooth is the most frequent hereditary neuromuscular diseases: there is no curative treatment at present, on the other hand precautionary measures can be taken (physiotherapy, port of splints, orthopaedic surgery and technical assistants). In the literature and in our recent study (evaluation of the pain in the disease of CMT - Reference center of the neuromuscular diseases - CHU Bow) the frequency of the pain is important varying from 66 to 96 % cases, affecting especially hands and lower limbs. The care of the pain in the Charcot syndrome Marie Tooth is not codified. The transcutaneous neurostimulation(TENS) is a not medicinal and not invasive therapeutics, without any brought back collateral effect, used at the same time in the chronic pain and acute since 1960, as well for the neuropathic pains that musculo-scrawny. No study was realized this day on the use of the TENS with analgesic aim in the CMT. We suggest studying the analgesic efficiency of the TENS in the Charcot syndrome Marie Tooth on the pains of lower limbs, the most frequent painful location in our recent works. The main objective will be to analyze the improvement of the pain of lower limbs, based on the decrease of the analogical visual scale(ladder) (EVA), at least 30 %. The secondary objectives will be to estimate repercussions on the functional capacities ( ONLS), the quality of life (SF(sci-fi) 12), the satisfaction (EVA), the global impression(printing) of change ( PGIC), the consumption of analgesic, DN4, NPSI (Neuropathic Pain Symptom Inventory), Concise Questionnaire of the Pains ( QCD), HAD (Hospital Anxiety and Depression scale).

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Aug 2012

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 20, 2012

Completed
1 month until next milestone

Study Start

First participant enrolled

August 31, 2012

Completed
11 months until next milestone

First Posted

Study publicly available on registry

August 8, 2013

Completed
23 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 31, 2013

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2014

Completed
Last Updated

June 16, 2026

Status Verified

June 1, 2026

Enrollment Period

1 year

First QC Date

July 20, 2012

Last Update Submit

June 15, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Visual Analogue Scale

    At 3 month

Study Arms (2)

TENS active

ACTIVE COMPARATOR

NEUROSTIMULATION TRANSCUTANEE AIMED ANALGESIC ACTIVE

Device: TENS

TENS placebo

PLACEBO COMPARATOR

NEUROSTIMULATION TRANSCUTANEE AIMED ANALGESIC PLACEBO

Device: TENS

Interventions

TENSDEVICE
TENS activeTENS placebo

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age included between 18 and 75 years
  • Affected by CMT confirmed on clinical, family criteria, electrophysiological and / or genetics
  • pain ≥ 3 months
  • EVA pain ≥ 4/10
  • patient having given his written consent and lit(enlightened)
  • patient susceptible to be followed regularly during at least 3 months
  • Patient member to the Social Security

You may not qualify if:

  • Expanding patients of associated neurological pathology
  • Patients having resorted to the TENS in the last 3 months
  • Medical history of cancers, collagen and quite other pathology which can interfere with the experimental procedure
  • Patient carrier of a pacemaker or an active implantable medical device
  • Cutaneous hurt on the territory to be stimulated
  • Venous or arterial thrombosis or thrombophlebitis in the territory to be stimulated
  • Patient under guardianship or deprived of all his liberties

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

CHU de Nice

Nice, 06000, France

Location

MeSH Terms

Conditions

Charcot-Marie-Tooth Disease

Interventions

Transcutaneous Electric Nerve Stimulation

Condition Hierarchy (Ancestors)

Hereditary Sensory and Motor NeuropathyNervous System MalformationsNervous System DiseasesHeredodegenerative Disorders, Nervous SystemNeurodegenerative DiseasesPolyneuropathiesPeripheral Nervous System DiseasesNeuromuscular DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesGenetic Diseases, Inborn

Intervention Hierarchy (Ancestors)

Electric Stimulation TherapyTherapeuticsPhysical Therapy ModalitiesRehabilitationAnalgesiaAnesthesia and Analgesia

Study Officials

  • Cécile RIBIERE

    Centre Hospitalier Universitaire de Nice

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 20, 2012

First Posted

August 8, 2013

Study Start

August 31, 2012

Primary Completion

August 31, 2013

Study Completion

July 31, 2014

Last Updated

June 16, 2026

Record last verified: 2026-06

Locations